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Purpose: To compare CT-, MR- and PET-CT based tumor length measurements in rectal cancer with
pathology.
Patients and Methods: Twenty-six rectal cancer patients underwent both MR and PET-CT imaging fol-
lowed by short-course radiotherapy (RT 5  5 Gy) and surgery within 3 days after RT. Tumor length
was measured manually and independently by 2 observers on CT, MR and PET. PET-based tumor length
measurements were also generated automatically using the signal-to-background-ratio (SBR) method. All
measurements were correlated with the tumor length on the pathological specimen.
Results: CT-based measurements did not show a valuable correlation with pathology. MR-based mea-
surements correlated only weakly, but still signiﬁcantly (Pearson correlation = 0.55 resp. 0.57;
p < 0.001). Manual PET measurements reached a good correlation with pathology, but less strong (Pear-
son correlation 0.72 and 0.76 for the two different observers) than automatic PET-CT based measure-
ments, which provided the best correlation with pathology (Pearson correlation of 0.91 (p < 0.001)).
Bland–Altman analysis demonstrated in general an overestimation of the tumor diameter using manual
measurements, while the agreement of automatic contours and pathology was within acceptable ranges.
A direct comparison of the different modalities revealed a signiﬁcant better precision for PET-based auto-
contours as compared to all other measurements.
Conclusion: Automatically generated PET-CT based contours show the best correlation with the surgical
specimen and thus provide a useful and powerful tool to accurately determine the largest tumor dimen-
sion in rectal cancer. This could be used as a quick and reliable tool for target delineation in radiotherapy.
However, a 3D volume analysis is needed to conﬁrm these results.
 2011 Elsevier Ireland Ltd Open access under the Elsevier OA license.
Radiotherapy and Oncology 98 (2011) 270–276Rectal cancer is a frequently occurring malignancy. Over the last
two decades multimodality treatment has led to important
improvements in the treatment of this disease. Preoperative RT, of-
ten combined with chemotherapy, followed by a Total Mesorectal
Excision (TME) has become the standard of care for most patients.
In this respect, modern imaging techniques are extremely impor-
tant in the preoperative workup for treatment decision making.
Endoscopic ultrasound (EUS) is most suitable for the evaluation
of superﬁcial tumors [1], whereas magnetic resonance (MR) imag-
ing provides more accuracy in determining the margin between
the tumor and the mesorectal fascia [2,3].
While there is growing interest in the possible role of FDG-PET in
response evaluation [4,5], until now, the use of 18F-ﬂuoro-2-deoxy-, Dr. Tanslaan 12, 6229 ET
en).
le.
nder the Elsevier OA license.glucose Positron Emission Tomography (FDG-PET) imaging has no
clearly deﬁned role in local staging of rectal cancer. However, a un-
ique advantage of FDG-PET-scanning is the ability to use the quanti-
tative information of the glucose uptake within the tumor to
automatically create a contour around the tumor. This auto-con-
touring process signiﬁcantly reduces the inter-observer variability
in the interpretation of images [6,7], as it eliminates the human fac-
tor, increases consistency, diminishes inter-observer variability and
also saves time. It is well known from other tumor sites that CT-
based tumor delineations result in a substantial inter-observer var-
iation [7,8]. Since there is a growing interest in the use of a boost in
the treatmentof rectal cancer, accurate delineationof the tumorvol-
umebecomes increasingly important [9,10]. However, presently the
evidenceof theuseof PET-CT in radiotherapyplanning for rectal can-
cer is limited [11]. Therefore, we need to compare this method with
the pathological specimen, before we can use PET as a reliable
method to deﬁne the Gross Tumor Volume (GTV) in rectal cancer.
Thus, the aim of the present study was to evaluate the accuracy of
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nio-caudal diameter of rectal tumors and to compare it with CT
and MR-based measurements.
Materials and methods
Since the purpose of this study was to directly correlate the ini-
tial tumor length measurements with pathology as gold standard,
we only included patients, who were referred for a short-course of
5 fractions of 5 Gy preoperative RT, followed by a TME within
3 days after the last fraction of radiotherapy. This preoperative
treatment is known to have no inﬂuence on the size of the tumor
if there is only a short time-window between completion of radio-
therapy and resection [12].
In total, 26 patients diagnosed with primary resectable rectal
cancer (T2-early T3, N0-1, with a predicted circumferential resec-
tion margin on MR of more than 2 mm) were enrolled. As part of
their preoperative workup, all patients had also been investigated
with an MR scan.
PET-CT imaging
Before the start of radiotherapy, all patients underwent a PET-
CT scan for treatment planning purposes using a PET-CT-simulator
(Biograph, SOMATOM Sensation 16 with an integrated ECAT ACCEL
PET scanner, Siemens, Knoxville, USA) with a spatial resolution of
approximately 6.5 mm in the center of the axial ﬁeld of view
(162 mm). Data acquisition was performed in 3D and the acquisi-
tion time per table position was 5 min. The acquired PET images
were corrected for scatter and attenuation using a CT based atten-
uation map. Image reconstruction was performed using FORE (Fou-
rier rebinning) and OSEM reconstruction (ordered subsets
expectation maximization, 4 iterations, 8 subsets) with an inter-
slice distance of 3.45 mm. The patients were instructed to fast for
at least 6 h prior to PET-imaging. The FDG was injected intrave-
nously, with the activity based on the patient weight (weight
[kg]  4 + 20 [MBq]). PET-CT imaging was started approximately
60 min after FDG injection. The patient was scanned in supine po-
sition. At the start of the examination, a native CT scan was made
from the top of the skull to the mid thigh. Scan parameters were
120 kV, 140 mA, a pitch of 1.25 and a 5 mm reconstructed section
thickness. Immediately thereafter, a PET-scan was performed, cov-
ering the identical transverse ﬁeld of view (500 mm).
Auto-delineation
For study purposes, the tumor was automatically delineated
using dedicated software (Esoft 5.0, Siemens MI, Erlangen, Ger-
many). An SBR method was used to ﬁnd for each patient a percent-
age threshold of the maximal SUV within a user deﬁned Volume of
Interest (VOI) around the tumor as previously described [13,14].
For each patient, the SBR was calculated, using the gluteus muscle
as relevant background. From the SBR, the corresponding threshold
percentage served as input for the SUV auto-delineation algorithm
in the Esoft software. The auto-delineation algorithm is based on
region growing [15]. Image voxels that are adjacent to one another
in a certain neighborhood are clustered or connected.
Using this method, an auto-contour was created for each pa-
tient (Fig. 1) and the maximal cranio-caudal length of the contour
was calculated automatically.Manual PET and CT measurements
All PET-CT scans were imported in our treatment planning sys-
tem (XiO/Focal 4.34.02, CMS Inc. Maryland Heights, MO, USA) and
PET-scans were read by two radiation-oncologists with experience
in the use of PET-CT for radiotherapy planning. A ﬁxed window-level setting was used as well as standard color settings. Maximal
tumor lengths were measured manually on a Focal workstation. At
a second time point (at least 4 weeks after the PET-measurements
to ensure that PET-measurements did not inﬂuence CT-
measurements), tumor lengths were measured by the same two
radiation-oncologists on the CT-images, without knowledge of
MR and PET images.Magnetic resonance (MR) imaging
All patients underwent MR-imaging of the pelvis as a part of
their preoperative workup. These scans were performed at the uni-
versity hospital and in the surrounding referring hospitals. The
ﬁeld strength of the MRmachines was 1 and 1.5 T, and the protocol
for rectal cancer MR imaging was regionally standardized, using
T2W FSE sequences in 3 planes [16]. The maximum tumor length
in cranio-caudal direction was measured manually on the PACS
viewing system on the sagittal T2-weighted images, with the use
of transversal and coronal projections when required. For this pur-
pose the standard measurement tool in the viewing system was
used. Measurements were performed independently by two expe-
rienced GI radiologists, blinded from any clinical information ex-
cept for the distance from the anal verge to the caudal margin of
the tumor on endoscopy and/or the distance to the tumor based
on digital rectal examination.Pathology
After resection, a standardized routine pathology examination
was performed by a pathologist specialized in gastro-intestinal
pathology using the protocol as described by Quirke et al. [17]. The
length of the tumor was carefully measured macroscopically with
a ruler, before slicing was done. The pathologist was blinded from
any information regarding the image-based tumor measurements.Statistical analysis
SPSS software (SPSS for Windows, version 15.0, SPSS Inc., Chi-
cago, IL), was used to perform statistical analysis. Tumor diameters
as measured with the different imaging modalities were compared
with pathology using linear regression, including the Pearson corre-
lation coefﬁcient. In addition to correlation analysis, Bland–Altman
analyses were performed to evaluate the absolute agreement of
themeasurementsbetween thedifferentmodalities [18]. Todirectly
compare thepredictive performance of the various tests amethod as
described by Sheiner and Beal [19] was used. Thismethod evaluates
the predictive performance of a test by calculating the prediction er-
ror and the bias. The prediction error is an indicator for the precision
of a test, while the bias gives information about the systematic com-
ponentof theprediction error. In otherwords, thebias reﬂects anun-
der- or overestimation of a test. Furthermore, this method gives the
opportunity to compare the performance of the different imaging
modalities.
Results
Tumor diameters varied from 1.6 to 8.0 cm on pathology exam-
ination (mean 4.2 cm, SD 1.4), from 2.9 to 10.8 cm on CT (mean
5.1 cm, SD 1.7 cm) from 3.1 to 7.6 cm on MR (mean 4.8 cm, SD
1.4) and from 2.2 to 8.1 cm on PET-scan (manual measurements,
mean 5.0 cm, SD 1.7 cm) resp. 2.0–8.0 cm (automatic measure-
ments, mean 4.2 cm, SD 1.4). Individual measurements are shown
in Table 1.
The results of thePearsoncorrelationanalyses are shown inFig. 2.
Measurement of the tumor length on CT showedno correlationwith
pathology for one observer and only a very weak correlation for the
Table 1
Individual measurements of each modality in cm.
Patient Pathology CTobs1 CTobs2 MRIobs1 MRIobs2 PETman1 PETman2 PETauto
1 6, 0 5, 8 5, 8 6, 9 8, 2 6, 8 6, 6 4, 8
2 4, 5 5, 6 7, 0 3, 7 5, 7 5, 5 6, 3 5, 0
3 4, 0 4, 0 3, 2 3, 4 2, 8 4, 2 4, 0 3, 8
4 8, 0 8, 0 9, 0 7, 3 7, 3 7, 8 8, 1 8, 0
5 3, 0 4, 0 3, 5 3, 5 3, 2 3, 9 4, 3 3, 0
6 4, 0 4, 3 4, 2 4, 4 4, 2 5, 0 4, 9 4, 2
7 2, 9 4, 3 3, 8 3, 9 3, 7 5, 6 5, 4 3, 2
8 5, 0 6, 0 5, 7 4, 1 5, 5 6, 2 6, 4 5, 2
9 4, 0 4, 6 5, 8 5, 4 4, 6 4, 3 3, 7 3, 7
10 3, 5 3, 5 2, 2 3, 6 4, 8 3, 8 2, 9 3, 0
11 4, 5 6, 3 4, 3 4, 8 4, 3 6, 6 6, 5 4, 8
12 5, 5 7, 3 6, 2 4, 3 3, 5 8, 2 7, 7 7, 0
13 4, 0 5, 5 4, 8 4, 7 4, 7 6, 0 5, 8 4, 9
14 4, 0 4, 0 4, 3 6, 4 6, 5 7, 4 7, 5 4, 5
15 5, 0 7, 1 6, 2 6, 3 4, 8 6, 6 6, 3 5, 7
16 3, 0 4, 6 1, 6 3, 2 3, 6 3, 0 2, 2 2, 0
17 3, 0 4, 5 3, 2 2, 5 3, 7 2, 6 3, 0 3, 0
18 6, 0 5, 0 4, 4 5, 5 5, 1 6, 8 6, 4 6, 5
19 4, 2 3, 9 4, 5 4, 5 3, 8 3, 2 3, 0 3, 6
20 3, 5 12, 4 9, 1 6, 9 7, 1 5, 4 6, 0 4, 5
21 3, 2 6, 1 1, 8 3, 9 3, 4 4, 2 3, 9 2, 8
22 3, 0 3, 6 5, 3 3, 1 3, 0 2, 8 3, 2 2, 9
23 1, 6 4, 5 3, 9 3, 6 3, 4 3, 1 3, 5 2, 4
24 3, 8 4, 7 5, 3 5, 9 4, 3 4, 2 3, 8 4, 0
25 4, 0 6, 3 5, 0 6, 7 4, 5 4, 4 4, 2 4, 1
26 3, 8 7, 2 4, 4 7, 1 7, 0 4, 0 3, 9 3, 6
Fig. 1. Images of, respectively, the surgical specimen, the corresponding CT-PET image and T2-weighted MR image of the same patient, with the tumor contour presented in
red.
272 Correlation of imaging modalities in rectal cancersecond observer (Pearson correlation = 0.34 (p = 0.09) resp. 0.50
(p = 0.01)). Intra-observer correlation for CT-scan was the weakest
of all modalities (Pearson correlation = 0.69; p < 0.001). The correla-
tion betweenMR and pathologywas somewhat stronger than CT for
both observers (Pearson correlation = 0.55 resp. 0.57; p < 0.001). In-
tra-observer correlation betweenbothMRobserverswas less strong
than for PET scan, but still considerable (Pearson correlation = 0.78
(p < 0.001)). The correlation between manual PET measurements
and pathology was stronger than for MR, resulting in a correlation
coefﬁcient of 0.76 for observer 1 and 0.72 for observer 2
(p < 0.001). Intra-observer correlation between the two PET-observ-
ers was very strong (Pearson correlation = 0.97, p < 0.001). The best
correlation was found between the automatic PET measurements
and the measured tumor length on pathology (Pearson correla-
tion = 0.91; p < 0.001).
A comparative analysis using Bland–Altman plots (Fig. 3) shows
that CT scans tend to overestimate tumor length, reﬂected by a
mean difference of 1.03 with limits of agreement 1.99 and 4.04.
This means that 95% of the diameters measured on CT lie within a
range of 1.99 to +4.04 cm from the true diameter as measured
in the pathology specimen. The agreement betweenMR and pathol-ogy proved to be better than CT but worse than automatic PET-
measurements: the mean difference reached 0.66 cm (limits of
agreement1.69 and 3.01). Formanualmeasurements on PET scan,
differences were somewhat larger (mean difference 0.91, limits of
agreement 1.23 and 3.05) than for automatically generated
contours on PET scans, which showed the best agreement with
pathology. For the majority of patients the agreement between
PET auto-contours and pathologywaswithin 1 cm. Themean differ-
ence was 0.13 cm and the limits of agreement were1.06 and 1.31.
The results of the analysis of precision and bias are shown in
Table 2. These results are in line with the observations in the
Bland–Altman plots: PET-auto-contours show the highest preci-
sion and the smallest bias and this precision was signiﬁcantly
better than any other measurement in this study, as can be gath-
ered from the 95% conﬁdence intervals.Discussion
This is the ﬁrst study demonstrating a strong correlation be-
tween the rectal tumor length measured in an automated way on
Fig. 2. Linear regression curves for maximal tumor diameter resulting from CT-imaging (2 observers, red and black) (A), MR-imaging (2 observers) (B), manual PET-contours
(2 observers) (C) and automatic PET-contours (D). The dotted line represents the ideal situation of absolute agreement between two modalities.
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based tumor measurements showed a stronger correlation with
pathology than CT, MR and manual PET measurements.
PET-based auto-delineation and correlation with pathology in
rectal cancer has been described in one other study [20]. This study
found only a modest correlation with pathology. However, these
patients were treated with a long course of chemoradiotherapy,
which certainly resulted in heterogeneous tumor downsizing, thus
strongly inﬂuencing the interpretation of correlative studies be-
tween pre-treatment images and pathology. Furthermore, a differ-
ent delineation algorithm was used. Our ﬁndings are in
concordance with the paper of Van Baardwijk et al. and Daisne
et al. who found that source-to-background ratio-based auto-
delineation showed a good correlation with pathology in, respec-
tively, lung and head and neck cancer [7,21]. Daisne et al. com-
pared FDG-PET with MR and CT and found PET to have the
strongest correlation with pathology in pharyngeal and laryngeal
cancer [21]. However, it should be mentioned that their results
were based on a relatively small group of 12 patients. An advan-
tage of their study is that they were able to make a reconstruction
of the tumor volume. Unfortunately, we were unable to reliably
measure the 3D tumor volume in the surgical specimen. However,
we made the assumption that the tumor length is indicative for thevolume, as has been shown before for cervical cancer [22]. For fu-
ture research we have planned to develop a method for accurate
volume measurements. A possible limitation of our study is that
the macroscopic tumor diameters may have been measured at dif-
ferent time points after resection. This may have led to different
degrees of shrinkage of the surgical specimen. No conclusive data
on tumor shrinkage has been reported for rectal cancer. However,
in prostate cancer, linear correction factors for tumor shrinkage be-
tween 1.04 and 1.14 have been described [23], indicating that the
inﬂuence of shrinkage might be rather low. Since the composition
of the tumor stroma of colorectal tumors in general is even more
compact than the ﬁbromuscular stroma of the prostate, we assume
that the shrinkage effect in colorectal tumors by formalin will be
even less than in the prostate.
Another characteristic of our patient group is that they all have
received short-course radiotherapy pre-operatively. In the Nether-
lands, preoperative radiotherapy has become the standard of care
for the large majority of rectal cancer patients. Therefore, it was
for ethical reasons not feasible to include patients who would only
undergo surgery. As mentioned earlier no downstaging has been
observed in the Dutch TME trial after 5  5 Gy. However, they ob-
served a small but statistically signiﬁcant difference in tumor
diameter between the irradiated and the non-irradiated group
Fig. 3. Bland–Altman plots showing the difference against mean for the three imaging modalities (A, CT; B, MR; C, manual PET contours; D, automatic PET contours). The thick
lines represent the conﬁdence intervals around the mean of difference, marking the level of agreement between the different imaging modalities.
Table 2
Predictive performance of the different modalities using the method as described by Sheiner and Beal [19].
PET auto PET manual MR CT Endoscopy
Precision 0.37 1.97 1.82 3.35 3.82
Bias 0.13 0.91 0.66 1.03 0.46
Difference in precision (95% CI)a 1.60 (2.71 to 0.50) 1.45 (2.70 to 0.19) 2.98 (4.00 to 1.96) 3.45 (7.60 to 0.70)
a Difference as compared to the performance of PET auto-contour.
274 Correlation of imaging modalities in rectal cancer(4.5 vs. 4.0 cm, p < 0.001). They did not report on reliable tumor
measurements at diagnosis, making it impossible to draw ﬁrm
conclusions whether this difference in tumor size may have been
caused by tumor shrinkage as a result of radiotherapy. In addition,
a substantial part of the patient group in the TME trial (57%) was
operated 4 or 5 days after completion of radiotherapy, while in
our patient group all patients were operated within 3 days. How-
ever, in order to have more certainty that tumor shrinkage did
not inﬂuence our results, we went on and analyzed the maximal
diameters on PET-CT scans of 21 rectal cancer patients who had
been imaged with PET-CT before and immediately after the ﬁfth
fraction of radiotherapy as part of a sequential PET-CT study [4].
The mean tumor diameters as measured by auto-contouring were
5.1 vs. 5.0 cm on pre- vs. post-radiotherapy scans (p = 0.13). This to
our opinion conﬁrms that at least up until day 5 of radiotherapy nosigniﬁcant tumor shrinkage has taken place. It is rather unlikely
that 3 further days at the time of surgery would still result in a
measurable down-sizing.
For tumors with smaller volumes it is important to rule out the
inﬂuence of partial volume effects (PVE) on PET-imaging [24]. PVE
typically occur if the tumor size is smaller than three times the spa-
tial resolution (that means 3  6.5 mm = 1.95 cm). As the smallest
maximal tumor diameter in this patient group as measured on
PET-scan was 2 cm, we do not expect that PVE had an important
inﬂuence on the data. Due to the limited spatial resolution of PET-
imaging, one may not expect PET-scan to be able to detect micro-
scopic tumor extension.
For the current radiotherapy treatment planning of rectal can-
cer, PET-imaging is only of limited value in the determination of
the radiation treatment ﬁeld borders, because the preoperative
J. Buijsen et al. / Radiotherapy and Oncology 98 (2011) 270–276 275treatment of rectal cancer normally includes a locoregional treat-
ment encompassing the whole posterior pelvis. However, new
developments of intensiﬁed regimens aiming at completely eradi-
cating the tumor might lead to the necessity of an accurate deﬁni-
tion of the tumor volume in order to avoid geographical misses and
to limit the volume of normal tissue being irradiated. So far, several
groups studied the use of PET-imaging for the delineation of rectal
tumors. Patel et al. found in a limited number of patients (n = 6),
that the use of PET-CT in radiotherapy planning for rectal cancer
resulted in a decrease in the inter-observer variability in boost tar-
get volumes [6]. Bassi et al. recently reported an important in-
crease in the target volume when using PET-CT data as compared
to only CT [25]. Anderson et al. showed a slight decrease in the
delineated volume based on PET-CT as compared to CT. The mean
overlap volume between the CT-based tumor volume and PET-
based tumor volume was 46.7% [26]. Very recently, the group of
Paskeviciute described the impact of FDG-PET-scan on planning
of neoadjuvant radiotherapy in rectal cancer [27]. They also found
a decrease in volumes deﬁned on basis of PET information. How-
ever, their CT volume consisted of the entire rectal circumference
at the level of the tumor, whereas the PET volume consisted of
the PET positive part of the rectal wall only with a 2 cm margin.
They found geographical misses in 46% of the patients. The use of
MR scans when delineating on CT is certainly helpful and is ex-
pected to diminish differences between contouring on CT only
and PET-CT. Another important difference between our study and
these two other studies is that they did not use automatic delinea-
tion software.
A disadvantage of the use of PET-imaging in colorectal cancer is
the fact that PET has only a very low sensitivity for nodal disease
[28]. For that reason PET-CT is not suitable for sub-boosting of
pathological nodes. Furthermore, PET-CT cannot reliably predict
the involvement of the mesorectal fascia [29]. Therefore, MR cer-
tainly has an important role in decision making in rectal cancer.
Another disadvantage of PET-scan is the low spatial resolution.
Therefore, it is difﬁcult to compare the inter-observer variabilities
between the different imaging modalities found in this study. It
cannot be entirely ruled out that the better agreement between
the two observers on PET-scan is partially the result of the lower
spatial resolution of PET as compared to CT and MRI.
As mentioned before, the use of auto-contours avoids inter-
observer differences [7]. Furthermore, it is well known that manual
delineation is largely operator-dependent [30]. Our own group pre-
viously compared delineation on CT with auto-contours generated
on PET-scans using static and dynamic PET-scans in rectal cancer
patients [31]. We found that manually drawn contours on CT were
signiﬁcantly larger than contours based on dynamic PET-scans. In
this cohort, no direct comparison was made between static PET-
scan contours using the SBR method and manual contours.
In conclusion, this is, to our knowledge, the ﬁrst study that con-
ﬁrms the accuracy of PET-CT-based tumor length measurements in
rectal cancer by pathology validation. PET-CT-based measure-
ments show a strong correlation with pathology compared to other
frequently used imaging modalities and can, therefore, be deﬁned
as a useful tool for the GTV delineation in rectal cancer.Conﬂicts of interest notiﬁcation
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